Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid Leukemia

Study Overview
=================
Brief Summary
-----------------
This is a prospective,open-label, phase1/2 study to evaluate the safety and efficacy of anti-FLT3 chimeric antigen receptor engineered T cell immunotherapy (CART) in the treatment of FLT3 positive relapsed or refractory acute myeloid leukemia.

Detailed Description
-----------------
The patients will receive infusion of anti-FLT3 CAR T-cells targeting FLT3 to evaluate the safety and efficacy of anti-FLT3 CAR T-Cells in relapsed or refractory acute myeloid leukemia.

Official Title
-----------------
Pilot Study of the Safety and Efficacy of Anti-FLT3 Chimeric Antigen Receptor Engineered T-Cells in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)

Conditions
-----------------
Acute Myeloid Leukemia

Intervention / Treatment
-----------------
* Biological: anti-FLT3 CAR-T


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: FLT3 positive relapsed/refractory acute myeloid leukemia Age 16-65 years. Left ventricular ejection fractions ≥ 0.5 by echocardiography Creatinine < 1.5x upper limit of normal. Aspartate aminotransferase/aspartate aminotransferase ≤ 2.5x upper limit of normal Total bilirubin ≤ 1.5x upper limit of normal Karnofsky performance status ≥ 60 Expected survival time ≥ 3 months (according to investigator's judgement) Exclusion Criteria: Patients are pregnant or lactating Uncontrolled active infection Grade III/IV cardiovascular disability according to the New York Heart Association Classification Active hepatitis B or hepatitis C infection Patients with HIV infection Patients with a history of seizure Patients with other contraindications considered unsuitable for participation in this study (according to investigator's judgement)

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CAR-T infusion<br>FLT3 positive relapsed or refractory acute myeloid leukemia | Biological: anti-FLT3 CAR-T<br>* Single intravenous infusion of anti-FLT3 CAR-T cells<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Adverse Events | Adverse events are evaluated with CTCAE V5.0 | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall response rate (ORR) | ORR includes CR, CRi, MLFS and PR. Complete remission (CR)：Bone marrow blasts <5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count >1.0x 10^9/L; platelet count >100x10^9/L. CR with incomplete hematologic recovery (CRi)：All CR criteria except for residual neutropenia (<1.0 x 109/L) or thrombocytopenia (<100 x 109/L). Morphologic leukemia-free state (MLFS): Bone marrow blasts <5%; absence of blasts with Auer rods; absence of extramedullary disease; no hematologic recovery required. Partial remission (PR): All hematologic criteria of CR; decrease of bone marrow blast percentage to 5% to 25%; and decrease of pretreatment bone marrow blast percentage by at least 50%. | 2 years | 
| Event-free survival (EFS) | time from enrollment to the date of primary refractory disease, or relapse from CR or CRi, or death from any cause | 2 years | 
| Cumulative incidence of relapse(CIR) | time from the date of achievement of a remission until the date of relapse | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
FLT3,CAR-T,AML